Latest & greatest articles for proton pump inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on proton pump inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on proton pump inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for proton pump inhibitors

21. Proton Pump Inhibitor Usage and the Risk of Mortality in Hemodialysis Patients Full Text available with Trip Pro

Proton Pump Inhibitor Usage and the Risk of Mortality in Hemodialysis Patients Long-term inappropriate proton pump inhibitors use (PPIs) is a matter of concern because of the risks associated with their long-term use in older patients with chronic conditions. The risk of PPI treatment in hemodialysis patients remains unexplored.We assessed the relationship between the use of PPIs and the risk of death in hemodialysis patients throughout a retrospective multicenter propensity score-matched study

2017 Kidney international reports

22. Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial (Abstract)

Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial Proton pump inhibitor (PPI)-amoxicillin-fluoroquinolone triple therapy is recommended as a second-line treatment of Helicobacter pylori infection in the Maastricht V/Florence Consensus Report. However, the eradication rate of this standard

2017 EvidenceUpdates

23. Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection Full Text available with Trip Pro

Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection Concomitant proton pump inhibitor (PPI) use reduces plasma concentrations of certain nonstructural protein 5A inhibitors, which are key components of modern hepatitis C infection (HCV) treatments. These reduced concentrations may decrease efficacy, leading to challenging treatment failures due to the development of resistance-associated

2017 Hepatology communications

24. Efficacy and Safety of Direct-acting Antivirals in Hepatitis C Virus-infected Patients Taking Proton Pump Inhibitors Full Text available with Trip Pro

Efficacy and Safety of Direct-acting Antivirals in Hepatitis C Virus-infected Patients Taking Proton Pump Inhibitors Background and Aims: Direct-acting antiviral (DAA) therapy is the cornerstone of the treatment of chronic hepatitis C virus (HCV) infection. Eradication of HCV, predicted by the attainment of a sustained virologic response (SVR) 12 weeks following DAA therapy, is the goal of this treatment. Interestingly, recent studies have reported the possible association between HCV-infected (...) patients with DAA therapy concomitant use of proton pump inhibitors (PPIs) and lower odds of achieving SVR. This meta-analysis was conducted to summarize all available data and to estimate this potential association. Methods: Comprehensive literature review was conducted by first searching the Medline and Embase databases through March 2017 to identify all studies that investigated the safety and efficacy of DAAs in patients with HCV infection taking PPIs versus those without PPIs. Adjusted point

2017 Journal of clinical and translational hepatology

25. No Association Between Proton Pump Inhibitor Use and Risk of Alzheimer's Disease Full Text available with Trip Pro

No Association Between Proton Pump Inhibitor Use and Risk of Alzheimer's Disease The objective of the study was to investigate whether proton pump inhibitor (PPI) use is associated with an increased risk of clinically verified Alzheimer's disease (AD).A Finnish nationwide nested case-control study MEDALZ includes all community-dwelling individuals with newly diagnosed AD during 2005-2011 (N=70,718), and up to four age-, sex-, and region of residence-matched comparison individuals for each case

2017 EvidenceUpdates

26. Gastric Ulcer Complications after the Introduction of Proton Pump Inhibitors into Clinical Routine: 20-Year Experience Full Text available with Trip Pro

Gastric Ulcer Complications after the Introduction of Proton Pump Inhibitors into Clinical Routine: 20-Year Experience The aim of this study was to analyze the admissions and the management of peptic ulcer disease (PUD) in a tertiary care surgical center.We evaluated the medical records of all patients admitted to the University Hospital of Tübingen, Germany, for treatment of PUD during 1989-2008. Patients were included into the study if the diagnosis was verified endoscopically or surgically (...) . Annual number of admissions, length of hospitalization, mortality rate, age, rate of non-steroidal anti-inflammatory drugs (NSAIDs) and proton pump inhibitor (PPI) medication, rate of Helicobacter pylori infection, and complications of PUD and surgery performed were recorded. Data were analyzed by descriptive analyses, Pearson's chi-square test, and regression analysis.This study included 614 admissions. The number of annual admissions (31 ± 12), the length of hospitalization (9 ± 3 days

2017 Visceral medicine

27. Deprescribing proton pump inhibitors

Deprescribing proton pump inhibitors 354 Canadian Family Physician • Le Médecin de famille canadien | Vol 63: may • mai 2017 Clinical Practice Guidelines Deprescribing proton pump inhibitors Evidence-based clinical practice guideline Barbara Farrell PharmD ACPR FCSHP Kevin Pottie MD CCFP MClSc FCFP Wade Thompson Taline Boghossian ACPR Lisa Pizzola MSc Farah Joy Rashid ACPR Carlos Rojas-Fernandez PharmD Kate Walsh ACPR Vivian Welch PhD Paul Moayyedi MB ChB PhD MPH Abstract Objective To develop (...) an evidence-based guideline to help clinicians make decisions about when and how to safely taper or stop proton pump inhibitors (PPIs); to focus on the highest level of evidence available and seek input from primary care professionals in the guideline development, review, and endorsement processes. Methods Five health professionals (1 family physician, 3 pharmacists, and 1 gastroenterologist) and 5 nonvoting members comprised the overall team; members disclosed conflicts of interest. The guideline process

2017 CPG Infobase

28. Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Use and Iron Deficiency Full Text available with Trip Pro

Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Use and Iron Deficiency Proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) suppress gastric acid production, which can inhibit iron absorption. However, few data exist regarding whether these medications increase the risk of clinical iron deficiency.A community-based case-control study evaluated the association between acid-suppressing medication use and the subsequent risk of iron deficiency. It contrasted 77,046 (...) day for at least 10 years (odds ratio, 4.27; 95% CI, 2.53-7.21). No similar strong associations were found for other commonly used prescription medications.Among patients without known risk factors for iron deficiency, gastric acid inhibitor use for ≥2 years was associated with an increased subsequent risk of iron deficiency. The risk increased with increasing potency of acid inhibition and decreased after medication discontinuation.Copyright © 2017 AGA Institute. Published by Elsevier Inc. All

2017 EvidenceUpdates

29. Clopidogrel and Proton Pump Inhibitor Use: A Review of the Evidence on Safety

Clopidogrel and Proton Pump Inhibitor Use: A Review of the Evidence on Safety Clopidogrel and Proton Pump Inhibitor Use: A Review of the Evidence on Safety | CADTH.ca Find the information you need Clopidogrel and Proton Pump Inhibitor Use: A Review of the Evidence on Safety Clopidogrel and Proton Pump Inhibitor Use: A Review of the Evidence on Safety Published on: March 14, 2017 Project Number: RC0874-000 - RD0036-000 Product Line: Research Type: Drug Report Type: Summary with Critical (...) Appraisal Result type: Report Question What are the harms of proton pump inhibitors used concomitantly with clopidogrel for patients requiring antiplatelet therapy following percutaneous coronary intervention? Key Message Although the findings across the studies were mixed, overall, the evidence favours clopidogrel antiplatelet therapy without PPIs. The evidence suggests that there are still some serious safety risks associated with the use of proton pump inhibitors (PPIs) with clopidogrel antiplatelet

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

30. [Optimal long-term use of proton pump inhibitors]

[Optimal long-term use of proton pump inhibitors] Usage optimal à long terme des inhibiteurs de la pompe à protons [Optimal long-term use of proton pump inhibitors] Usage optimal à long terme des inhibiteurs de la pompe à protons [Optimal long-term use of proton pump inhibitors] Tremblay E, Tardif M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation Tremblay E, Tardif M. Usage optimal à long terme des inhibiteurs de la pompe à protons. [Optimal long-term use of proton pump inhibitors] Quebec: Institut national d'excellence en sante et en services sociaux (INESSS). 2016 Authors' conclusions Upon gathering information from good clinical practice recommendations and during multiple consultations, INESSS made the following observations: • Prescribing PPIs is unwarranted in many cases. • It will take more than clinical tools and training

2017 Health Technology Assessment (HTA) Database.

31. Proton Pump Inhibitors and Kidney Disease—GI Upset for the Nephrologist? Full Text available with Trip Pro

Proton Pump Inhibitors and Kidney Disease—GI Upset for the Nephrologist? Widely regarded as safe and effective, proton pump inhibitors (PPIs) are among the most commonly used medications in the world today. However, a spate of observational studies suggest an association between PPI use and adverse events, including infection, bone fracture, and dementia. This review details evidence linking the use of PPI therapy to the development of kidney disease, including early case reports of acute

2017 Kidney international reports

32. Proton Pump Inhibitors (PPIs): Is Perpetual Prescribing Inevitable?

Proton Pump Inhibitors (PPIs): Is Perpetual Prescribing Inevitable? Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,500 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca (...) June 26, 2017 Proton Pump Inhibitors (PPIs): Is Perpetual Prescribing Inevitable? Clinical Question: How successful are attempts to stop PPIs and how can clinicians improve chances of success? Bottom Line: Using a range of deprescribing strategies, about 25% of patients with gastroesophageal reflux disease (GERD) or dyspepsia can stop PPI use and another 30-50% can decrease their dose. Older patients and those who taper appear more successful in stopping PPIs. Evidence: • Clustered randomized

2017 Tools for Practice

33. Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study. Full Text available with Trip Pro

Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study. Objective To examine the risk of community acquired pneumonia before and after prescription of proton pump inhibitor (PPI) and assess whether unmeasured confounding explains this association.Design Cohort study and self controlled case series.Setting Clinical Practice Research Datalink (1990 to 2013) in UK.Participants Adult patients with a new prescription for a PPI individually

2016 BMJ

34. A systematic review of the comparative effectiveness of proton pump inhibitors for the treatment of adult patients with gastroesophageal reflux disease or peptic ulcer disease

A systematic review of the comparative effectiveness of proton pump inhibitors for the treatment of adult patients with gastroesophageal reflux disease or peptic ulcer disease A systematic review of the comparative effectiveness of proton pump inhibitors for the treatment of adult patients with gastroesophageal reflux disease or peptic ulcer disease | Therapeutics Initiative Independent Healthcare Evidence > > A systematic review of the comparative effectiveness of proton pump inhibitors (...) for the treatment of adult patients with gastroesophageal reflux disease or peptic ulcer disease This was produced by the Drug Assessment Working Group of the Therapeutics Initiative at the request of the Pharmaceutical Services Division (PSD) of the British Columbia Ministry of Health as part of the Drug Effectiveness Review Project (DERP), a class review of proton pump inhibitors (PPIs) for the treatment of adult patients with symptomatic GERD or PUD. Research questions Four research questions were

2016 Therapeutics Letter

35. Comparative effectiveness of proton pump inhibitors

proton pump inhibitors (PPIs). 1-6 These drugs work by irreversibly inhibiting gastric H+K+ ATPase (the proton pump) in the stomach. They inhibit both basal and stimulated acid secretion and are used in a number of clinical set- tings: gastroesophageal reflux disease (GERD), reflux esophagitis, peptic ulcer disease (PUD), and symptoms associated with stomach acid such as heartburn and acid indigestion. Are there any important differences between the different drugs in the class? We have conducted two (...) Comparative effectiveness of proton pump inhibitors March - April 2016 99 © Mailing Address: Therapeutics Initiative The University of British Columbia Department of Anesthesiology, Pharmacology & Therapeutics 2176 Health Sciences Mall Vancouver, BC Canada V6T 1Z3 Comparative effectiveness of proton pump inhibitors Comparative trials of PPIs in adult patients with symptomatic PUD Based on 6 RCTs in 1753 patients, esomeprazole was not significantly different from other PPIs for most outcome

2016 Therapeutics Letter

36. Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors Full Text available with Trip Pro

Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors Polymorphisms in genes encoding drug metabolizing enzymes may lead to varied enzyme activity and inter-individual variability in drug efficacy and/or toxicity. Since CYP2C19 and CYP3A4 genes code for enzymes involved in metabolizing wide variety of drugs including proton pump inhibitors, we sought to identify polymorphisms in these genes in order to study their impact (...) on drug metabolism in subjects.DNA was isolated from healthy individuals including tribals and genotyped for 11 single nucleotide polymorphisms in CYP2C19 and 6 polymorphisms in CYP3A4. Individuals were categorized into different phenotypes based on their drug metabolizing genotype. Volunteers from each group were administered proton pump inhibitors (Esomeprazole, Pantoprazole; 40 mg/day) for 5 days followed by pharmacokinetic studies and measurement of intra-gastric pH.Of the 17 polymorphisms studied

2016 Meta gene

37. Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Proton Pump Inhibitors Full Text available with Trip Pro

Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Proton Pump Inhibitors Subacute cutaneous lupus erythematosus (SCLE) is an autoimmune disease that may be induced by proton pump inhibitors (PPIs) in at-risk populations. The US FDA does not recognize SCLE as an adverse event associated with PPIs. We queried the FDA Adverse Event Reporting System database, which contains adverse event case reports submitted by the public as well as by industry, and analyzed the data to quantify

2016 Drugs - real world outcomes

38. Pre-Endoscopic Intravenous Proton Pump Inhibitors for Emergency Department Patients with Upper Gastrointestinal Bleeds: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines

Pre-Endoscopic Intravenous Proton Pump Inhibitors for Emergency Department Patients with Upper Gastrointestinal Bleeds: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines Pre-Endoscopic Intravenous Proton Pump Inhibitors for Emergency Department Patients with Upper Gastrointestinal Bleeds: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines | CADTH.ca Find the information you need Pre-Endoscopic Intravenous Proton Pump Inhibitors for Emergency Department (...) Patients with Upper Gastrointestinal Bleeds: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines Pre-Endoscopic Intravenous Proton Pump Inhibitors for Emergency Department Patients with Upper Gastrointestinal Bleeds: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines Published on: February 5, 2016 Project Number: RC0740-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

39. Are We Overusing Proton Pump Inhibitors?

Are We Overusing Proton Pump Inhibitors? Are We Overusing Proton Pump Inhibitors? – Clinical Correlations Search Are We Overusing Proton Pump Inhibitors? November 13, 2015 7 min read [1]. PPIs are the most potent inhibitors of gastric secretion and are used to treat common upper gastrointestinal disorders, such as gastroesophageal reflux disease (GERD) and peptic ulcer disease. The effectiveness of PPIs and their perceived low toxicity profile have led to their popularity and even inappropriate (...) such as ranitidine. PPIs work by irreversibly inhibiting the parietal cell H+K+ATPase, a pump that actively secretes protons into the gastric lumen in exchange for potassium ions. Because PPIs take several days to cut down maximal acid output, [2]. Upon discontinuation of the drug, patients can experience rebound acid hypersecretion due to hypergastrinemia, leading to worsening of GERD symptoms. These are reasons that many physicians simply keep patients on daily PPIs indefinitely. Currently

2015 Clinical Correlations

40. [Notice of the impact of the decrease of the maximum payable amount for the class of proton pump inhibitors]

[Notice of the impact of the decrease of the maximum payable amount for the class of proton pump inhibitors] Avis sur l'impact de la baisse du prix maximal payable sur la classe des inhibiteurs de la pompe à protons [Notice of the impact of the decrease of the maximum payable amount for the class of proton pump inhibitors] Avis sur l'impact de la baisse du prix maximal payable sur la classe des inhibiteurs de la pompe à protons [Notice of the impact of the decrease of the maximum payable amount (...) for the class of proton pump inhibitors] Jehanno C, Robitaille J, Bouchard S Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Jehanno C, Robitaille J, Bouchard S. Avis sur l'impact de la baisse du prix maximal payable sur la classe des inhibiteurs de la pompe à protons. [Notice of the impact of the decrease of the maximum payable amount for the class

2015 Health Technology Assessment (HTA) Database.